Yael Levy-Shraga, Shelly Levi, Ravit Regev, Shoshana Gal, Avivit Brener, Yael Lebenthal, David Gillis, David Strich, Amnon Zung, Roxana Cleper, Yael Borovitz, Rachel Bello, Ariel Tenenbaum, Zvi Zadik, Miriam Davidovits, Leonid Zeitlin, Dov Tiosano
UNLABELLED: To assess the long-term efficacy of burosumab for pediatric patients with X-linked hypophosphatemia, focusing on linear growth. This multi-center retrospective study included 35 pediatric patients who began treatment with burosumab between January 2018 and January 2021. We collected clinical data, anthropometric measurements, laboratory results, and Rickets Severity Score (RSS), from 2 years prior to treatment initiation and up to 4 years after. Burosumab was initiated at a mean age of 7...
September 14, 2023: European Journal of Pediatrics